Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) Director Arsani William sold 814,874 shares of the company’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $4.25, for a total value of $3,463,214.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Design Therapeutics Stock Up 3.8 %
NASDAQ DSGN opened at $4.41 on Wednesday. The firm has a market cap of $249.14 million, a price-to-earnings ratio of -4.20 and a beta of 1.83. The business has a 50-day moving average price of $4.01 and a 200-day moving average price of $3.62. Design Therapeutics, Inc. has a twelve month low of $1.94 and a twelve month high of $7.66.
Design Therapeutics (NASDAQ:DSGN – Get Free Report) last released its quarterly earnings data on Monday, August 5th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. Research analysts expect that Design Therapeutics, Inc. will post -1.02 EPS for the current fiscal year.
Hedge Funds Weigh In On Design Therapeutics
Wall Street Analyst Weigh In
DSGN has been the subject of a number of analyst reports. Piper Sandler upgraded Design Therapeutics from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $6.00 to $12.00 in a research report on Tuesday, May 7th. Royal Bank of Canada restated a “sector perform” rating and issued a $4.00 price target on shares of Design Therapeutics in a research report on Tuesday, August 6th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Design Therapeutics currently has an average rating of “Hold” and an average price target of $6.60.
Check Out Our Latest Stock Analysis on DSGN
Design Therapeutics Company Profile
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
See Also
- Five stocks we like better than Design Therapeutics
- How to Evaluate a Stock Before Buying
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- EV Stocks and How to Profit from Them
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.